Drug Trial Radar · NCT04037254
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Oct 8, 2019
Primary completion
Jul 1, 2024
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding niraparib to the usual care may lower the chance of prostate cancer growing or returning.
Conditions
- Prostate Adenocarcinoma
- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
Interventions
Gonadotrophin Releasing HormoneBiological
Receive standard of care GnRH agonist androgen suppression therapy
Intensity-Modulated Radiation TherapyRadiation
Undergo standard of care IMRT
NiraparibDrug
tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Disease-free Until Completion of Treatment (2 Years From Start of ADT)Time frame: Baseline to completion of treatment (two years from start of ADT)
Locations
95 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
City of Hope Comprehensive Cancer Center
Duarte, California
Cedars-Sinai Medical Center
Los Angeles, California
Fremont - Rideout Cancer Center
Marysville, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
City of Hope Upland
Upland, California
Helen F Graham Cancer Center
Newark, Delaware
Medical Oncology Hematology Consultants PA
Newark, Delaware
George Washington University Medical Center
Washington D.C., District of Columbia
Grady Health System
Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Emory Saint Joseph's Hospital
Atlanta, Georgia
CTCA at Southeastern Regional Medical Center
Newnan, Georgia
Alton Memorial Hospital
Alton, Illinois
Northwestern University
Chicago, Illinois
Rush MD Anderson Cancer Center
Chicago, Illinois
Carle Cancer Center
Urbana, Illinois
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa
University of Kansas Cancer Center
Kansas City, Kansas
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
McLaren Cancer Institute-Bay City
Bay City, Michigan
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan
McLaren Cancer Institute-Clarkston
Clarkston, Michigan
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan
Henry Ford Medical Center-Fairlane
Dearborn, Michigan
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Hospital
Detroit, Michigan
Weisberg Cancer Treatment Center
Farmington Hills, Michigan
McLaren Cancer Institute-Flint
Flint, Michigan
Singh and Arora Hematology Oncology PC
Flint, Michigan
Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan
Mid-Michigan Physicians-Lansing
Lansing, Michigan
McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.